Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.96 - $2.23 $16,320 - $37,910
17,000 New
17,000 $23,000
Q1 2024

May 07, 2024

BUY
$3.16 - $4.66 $337,488 - $497,688
106,800 Added 267.67%
146,700 $573,000
Q4 2023

Feb 14, 2024

BUY
$0.23 - $9.77 $9,177 - $389,823
39,900 New
39,900 $175,000

Others Institutions Holding TPST

About Tempest Therapeutics, Inc.


  • Ticker TPST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 10,418,900
  • Market Cap $9.27M
  • Description
  • Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...
More about TPST
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.